P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders
CNS Neuroscience & Therapeutics · 2026-09 · 32 (9)
DOI: 10.1002/cns.71139 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 05.09.2026. Verfasst von Yajing Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Carbazoles, Mitochondria, Brain Diseases, Neuroprotective Agents. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Innovative and Enterpreneurial Talent Programme, Suzhou Medical Health Science and Technology Innovation Project.
Abstract (Originalsprache)
Background
P7C3 compounds are aminopropyl carbazole derivatives identified through phenotypic screening for proneurogenic activity. They directly activate nicotinamide phosphoribosyltransferase (NAMPT), the rate‐limiting enzyme in the NAD + salvage pathway. However, a comprehensive synthesis of their mechanisms and therapeutic potential across neurological disorders is currently lacking.
Methods
A systematic literature review was conducted in PubMed, Web of Science, and Scopus to synthesize the discovery trajectory, structure–activity relationships, molecular mechanisms, and preclinical efficacy of P7C3 compounds. The following keyword combinations were used: (“P7C3” OR “P7C3 compound”) AND (“NAMPT” OR “NAD+” OR “sirtuin” OR “mitochondria”) AND (“neuroprotection” OR “neurodegenerative”).
Results
P7C3 elevates intracellular NAD + levels, engages SIRT1 and SIRT3 deacetylase cascades, enhances mitochondrial quality control and attenuates oxidative stress. This review discusses the discovery, structure–activity relationships, and molecular mechanisms of P7C3, with a particular emphasis on mitochondrial dynamics and redox homeostasis. The efficacy of P7C3 in preclinical studies was evaluated across Alzheimer's disease (AD), Parkinson's disease (PD), traumatic brain injury (TBI), ischemic stroke, depression, and chemotherapy‐induced neuropathy. These neuroprotective effects occur independently of disease‐specific aggregates. Challenges hindering clinical application include the on‐target safety of NAMPT activation given the concurrent development of NAMPT inhibitors for tumorigenesis, the absence of validated predictive biomarkers, and the failure of prior NAMPT‐targeting trials.
Conclusions
P7C3 illustrates how phenotypic screening coupled with target deconvolution can yield therapeutic candidates with potential applications across a broad spectrum of neurological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Chao Gu
Förderung
- National Natural Science Foundation of China
- Jiangsu Innovative and Enterpreneurial Talent Programme
- Suzhou Medical Health Science and Technology Innovation Project
- Suzhou Health Talent Plan Talent Research Project
Zitieren
APA
Chen, Y., Du, X., Li, F., Yuan, S., Wang, W., Zhu, Z., Wang, M., & Gu, C. (2026). P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders. CNS Neuroscience & Therapeutics, 32(9). https://doi.org/10.1002/cns.71139
Vancouver
Chen Y, Du X, Li F, Yuan S, Wang W, Zhu Z, et al. P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders. CNS Neuroscience & Therapeutics. 2026;32(9). doi:10.1002/cns.71139
BibTeX
@article{Chen2026,
author = {Chen, Yajing and Du, Xiaohuan and Li, Fang and Yuan, Shuwei and Wang, Wenjing and Zhu, Zengyan and Wang, Mei and Gu, Chao},
title = {P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {9},
doi = {10.1002/cns.71139}
}
EUVIMED